JNJ
Another courtroom cameo
Johnson & Johnson is back in the legal crosshairs. Boston Scientific has sued a J&J subsidiary, accusing it of patent infringement tied to a cardiology device.
Why investors should care
Patent fights can be slow-burn messes: expensive to defend, annoying to manage, and sometimes surprisingly expensive to settle. If Boston Scientific’s claims gain traction, J&J could face:
- legal costs that nibble at profits
- potential settlement or licensing payments
- uncertainty around a cardiology product or platform
The bigger picture
This isn’t the flashy kind of news that makes a stock moon before lunch. But for a mega-cap like J&J, litigation like this is part of the background noise that can quietly add risk — especially when it touches a medical device business, where patents are basically the bouncer at the club.
Big picture: it’s not the end of the world, but it is another reminder that in healthcare, the courtroom can be just as important as the lab.